Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CNS Pharmaceuticals, Inc.
Report date December 06, 2022 · Filed August 01, 2023
Section 16 reporting ended · disclosed 2023-08-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 156,807 |
Last balance in matching sequence
After 2023-03-28 transaction · row 17
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
17 source rowsRow 1 · 2022-12-06 · Sale · Disposed 5,500 · Balance 245,605 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 2 · 2022-12-07 · Sale · Disposed 5,500 · Balance 240,105 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 3 · 2022-12-08 · Sale · Disposed 5,500 · Balance 234,605 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 4 · 2022-12-09 · Sale · Disposed 2,798 · Balance 231,807 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 5 · 2023-03-10 · Sale · Disposed 5,000 · Balance 226,807 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 6 · 2023-03-13 · Sale · Disposed 5,000 · Balance 221,807 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 7 · 2023-03-14 · Sale · Disposed 5,000 · Balance 216,807 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 8 · 2023-03-15 · Sale · Disposed 5,000 · Balance 211,807 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 9 · 2023-03-16 · Sale · Disposed 5,000 · Balance 206,807 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 10 · 2023-03-17 · Sale · Disposed 5,000 · Balance 201,807 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 11 · 2023-03-20 · Sale · Disposed 5,000 · Balance 196,807 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 12 · 2023-03-21 · Sale · Disposed 5,000 · Balance 191,807 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 13 · 2023-03-22 · Sale · Disposed 5,000 · Balance 186,807 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 14 · 2023-03-23 · Sale · Disposed 10,000 · Balance 176,807 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 15 · 2023-03-24 · Sale · Disposed 5,000 · Balance 171,807 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 16 · 2023-03-27 · Sale · Disposed 5,000 · Balance 166,807 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Row 17 · 2023-03-28 · Sale · Disposed 10,000 · Balance 156,807 F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc.
Moleculin Biotech, Inc.
Report date August 20, 2020 · Filed August 24, 2020
Section 16 reporting ended · disclosed 2020-08-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2030-08-20 | Direct | 100,000 |
Reported balance
After 2020-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-08-20 · Grant · Acquired 100,000 · Balance 100,000 F2: Issued in connection with the reporting person providing services to the Company. F1: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.
F2: Issued in connection with the reporting person providing services to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 28, 2023 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 10,000 | $1.04 | $10,400.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 17 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 156,807 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| March 27, 2023 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 5,000 | $1.09 | $5,450.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 16 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 166,807 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| March 24, 2023 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 5,000 | $1.08 | $5,400.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 15 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 171,807 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| March 23, 2023 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 10,000 | $1.08 | $10,800.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 14 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 176,807 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| March 22, 2023 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 5,000 | $1.08 | $5,400.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 13 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 186,807 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| March 21, 2023 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 5,000 | $1.10 | $5,500.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 12 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 191,807 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| March 20, 2023 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 5,000 | $1.08 | $5,400.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 11 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 196,807 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| March 17, 2023 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 5,000 | $1.13 | $5,650.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 10 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 201,807 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| March 16, 2023 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 5,000 | $1.24 | $6,200.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 9 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 206,807 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| March 15, 2023 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 5,000 | $1.22 | $6,100.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 8 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 211,807 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| March 14, 2023 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 5,000 | $1.35 | $6,750.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 7 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 216,807 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| March 13, 2023 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 5,000 | $1.30 | $6,500.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 6 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 221,807 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| March 10, 2023 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 5,000 | $1.29 | $6,450.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 5 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 226,807 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| December 09, 2022 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 2,798 | $2.43 | $6,799.14 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 4 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 231,807 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| December 08, 2022 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 5,500 | $2.40 | $13,200.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 3 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 234,605 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| December 07, 2022 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 5,500 | $2.46 | $13,530.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 2 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 240,105 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| December 06, 2022 Filed Aug 1, 2023 17:10 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | SaleCommon Stock | 5,500 | $2.47 | $13,585.00 |
DisclosureSEC source: 0000897069-23-001044 · form4.xml · nonDerivative · entry 1 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 245,605 F1 · ownership.nature: Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 20:04 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.96 | Not disclosed |
DisclosureSEC source: 0001659617-20-000206 · wf-form4_159829941790393.xml · derivative · entry 1 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-08-20 F2 · price: Issued in connection with the reporting person providing services to the Company. F1 · derivative.exercise_date: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| May 05, 2020 Filed Jan 25, 2022 16:05 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | OtherCommon Stock | 1,495,867 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-22-000460 · ownership.xml · nonDerivative · entry 1 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,533,133 F1 · price: The shares are held by a limited liability company for which the reporting person's adult child is the sole manager and adult children are sole members. Prior to May 5, 2020, the reporting person was a manager of the limited liability company. The reporting person ceased to be a manager of the limited liability company on May 5, 2020, and since such date has not had any voting or dispositive power over the shares held by the limited liability company. The reporting person has never had a pecuniary interest in the limited liability company. F2 · ownership.nature: Consists of: (i) 7,333,133 shares of common stock held by a limited liability company; and (ii) 200,000 shares held by Houston Pharmaceuticals, Inc. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 22:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | SaleCommon Stock | 100,000 | $1.70 | $170,300.00 |
DisclosureSEC source: 0001144204-17-044232 · v473534_4.xml · nonDerivative · entry 1 Priebe Waldemar · CIK 0001678516 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,781,573 F1 · kind: The reporting person entered into a private sale agreement for the shares of common stock set forth in the table. F2 · balance_after: In addition to the shares held directly by the reporting person, The reporting person is a shareholder and control person of IntertechBio Corp. IntertechBio Corp. holds 630,000 shares of Issuer common stock. Pursuant to General Instruction 5(b)(iv) of Form 3, the amount set forth in the table represents the reporting person's proportionate interest in the Issuer common stock beneficially owned by IntertechBio Corp. The reporting person is also a shareholder and control person of Houston Pharmaceuticals, Inc. Houston Pharmaceuticals, Inc. holds 629,000 shares of Issuer common stock. Pursuant to General Instruction 5(b)(iv) of Form 3, the amount set forth in the table represents the reporting person's proportionate interest in the Issuer common stock beneficially owned by Houston Pharmaceuticals, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.